Longidaza

Longizada suppositories are a medicine with proteolytic properties.

Indications Longidase

Suppositories are indicated for complex treatment of pathologies that develop with hyperplasia in the area of connective tissues. The medicine is prescribed in the following cases:

• urology – treatment of chronic prostatitis, interstitial cystitis, as well as strictures of the ureters with the urethra, prostate adenoma (in the early stages of the disease), as well as Peyronie's disease;
• gynecology – the appearance of adhesions in the pelvic area, accompanied by inflammatory processes in the internal genital organs (among the diseases are chronic endometritis, Asherman's syndrome, and tubal-peritoneal infertility);
• surgery – to eliminate hypertrophic scars (including those resulting from injuries, burns, operations, and pyoderma), adhesions that develop as a result of operations in the peritoneum, and in addition, long-term non-healing wounds;
• dermatovenereology and cosmetology – elimination of developing hypertrophic or keloid scars that develop after surgeries, injuries, burns or pyoderma, and also for the treatment of limited forms of scleroderma;
• phthisiology and pulmonology – pulmonary pneumosclerosis, infiltrative or cavernous-fibrous form of tuberculosis, pulmonary tuberculoma, fibrosing alveolitis, as well as siderosis with pneumofibrosis, as well as interstitial form of pneumonia and pleurisy;
• Orthopedics – treatment of limited joint mobility, hematomas, Bechterew's disease, and arthrosis.

In addition, suppositories can be used to increase the bioavailability of antimicrobial drugs, as well as local anesthetics in pulmonology, urology, as well as dermatovenereology and gynecology.

According to medical prescription, Longidaza can be used to prevent the formation of scars or strictures after surgical operations.

Pharmacodynamics

Longidaza is a complex of macromolecules included in the proteolytic enzyme hyaluronidase and having a high-molecular carrier. The carrier is an element from the category of derivatives of N-oxy-poly-1,4-ethylene piperazine. Longidaza is distinguished by the powerful activity of hyaluronidase (it is several times higher than the activity of native type hyaluronidase), which develops due to the fact that the conjugate is more resistant to the effects of retarding components, as well as temperatures.

The drug has powerful anti-inflammatory, immunostimulating, anti-edematous, antioxidant, and chelating properties. Hyaluronidase contains specific substrates, which are glycosaminoglycans - elements of connective tissues, including chondroitin-4-sulfate, as well as chondroitin-6-sulfate, and in addition, hyaluronan with chondroitin. The glycolysis process allows to reduce the viscosity of glycosaminoglycans, and with it the ability to synthesize metal ions with water. As a result, tissue trophism and permeability increase, hematomas are absorbed and swelling decreases, and in addition, the elasticity of areas where scars are located improves. Glycolysis of these elements also allows to reduce the severity or completely remove limited joint mobility and adhesions.

The drug will be most effective if used in the early stages of treatment of the disease.

The antioxidant property of Longidaza is provided by the ability of the active component to synthesize iron ions. These substances activate the response of free radicals, and in addition, stimulate the processes of collagen binding and slowing down hyaluronidase.

The pronounced antifibrotic effect of the drug has been proven by numerous biochemical, electron microscopic, and histological tests carried out on a pneumofibrosis sample.

The suppositories normalize the process of synthesis of inflammation conductors, help strengthen humoral immunity, and at the same time reduce the severity of inflammation during the acute stage of the disease.

The medicine can be used to prevent the development of adhesions or scars after operations, because it does not have a negative effect on the course of the postoperative period and does not provoke the progression of infection. In addition, it does not interfere with the recovery process inside bone tissue.

Thanks to the use of drugs, the level of bioavailability of other drugs increases, and along with this, the development of the effect of the use of local anesthetics accelerates.

Longidaza has low toxicity, the active substance of the drug does not affect the immune and reproductive systems. It does not have mutagenic, carcinogenic, or teratogenic properties.

[ 1 ], [ 2 ]

Pharmacokinetics

After rectal administration, the active substance of the drug is quickly absorbed into the systemic bloodstream, after which it reaches maximum levels within 1 hour. After rectal or vaginal administration, the bioavailability of the substance is 70%.

The active component is able to pass through the BBB, placenta, and ophthalmologic barrier. The carrier inside the body disintegrates, taking the form of oligomers, excreted through the kidneys in 2 phases.

The half-life of the substance after vaginal or rectal administration is 42-84 hours.

[ 3 ]

Dosing and administration

Suppositories with the medicine should be administered vaginally (from a lying position before bedtime) or rectally (only after bowel movement). The dose size, as well as the duration of the course of therapy, are prescribed by the attending physician.

For the treatment of urological pathologies, it is necessary to administer 1 suppository rectally once every 48 hours. After 10 suppositories have been administered, the interval between applications should be increased to 2-3 days. In total, 20 suppositories should be used per course.

When eliminating gynecological diseases, 1 suppository is inserted vaginally or rectally once every 3 days. The general course of therapy includes 10 suppositories. If necessary, maintenance treatment may be prescribed after the main course.

For the treatment of dermatovenereological diseases, it is necessary to insert 1 suppository rectally once every 2-3 days. In general, the entire course includes 10-15 suppositories.

To eliminate surgical disorders, rectal administration of 1 suppository is prescribed once with an interval of 2-4 days. In general, the course usually consists of 10 suppositories.

In the course of treatment of phthisiological and pulmonary diseases, rectal administration of 1 suppository is prescribed once at intervals of 3-5 days. The general course includes the administration of 10-20 suppositories of the drug.

A repeat therapeutic course can usually be prescribed at least 3 months after the previous one. Maintenance treatment involves administering 1 suppository once at intervals of 5-7 days for 3-4 months.

For people who have recently experienced bleeding, as well as those suffering from chronic renal failure, the recommended dosage is no more than 1 suppository once every 7 days.

[ 8 ]

Use Longidase during pregnancy

It is prohibited to prescribe Longidaza to women during lactation and to pregnant women.

If it is impossible to refuse to use the drug during lactation, breastfeeding must be discontinued for the duration of treatment.

Contraindications

Among the contraindications of the drug:

• prohibited in case of patient intolerance to the components of the drug;
• should not be used to treat people with severe renal dysfunction or malignant tumors;
• not prescribed to children under 12 years of age.

It is prescribed with caution to people with kidney failure, as well as to those who have recently experienced bleeding. In addition, caution is required if the patient has an acute infectious process (in such a situation, suppositories can be prescribed only in combination with antimicrobial drugs).

[ 4 ], [ 5 ], [ 6 ]

Side effects Longidase

As a result of using the drug, side effects such as local or systemic allergic reactions may develop sporadically.

[ 7 ]

Interactions with other drugs

The medicine enhances the properties of diuretic and antimicrobial drugs, as well as local anesthetics when combined with them.

In case of simultaneous use with estrogens, salicylates, corticotropin, and antihistamines (all in high doses), the properties of Longidaza are weakened.

It is prohibited to combine the drug with phenytoin, furosemide, and benzodiazepines.

[ 9 ], [ 10 ], [ 11 ]

Storage conditions

Suppositories should be stored at temperatures within the range of 8-15 ^o C. The conditions for the place where the medicine is stored are standard.

[ 12 ]

Shelf life

Longidaza suppositories can be used for 2 years from the date of release of the drug.